Businesses around the world are shifting into overdrive to help battle the coronavirus, providing everything from rubber gloves and ventilators to diagnostic tools and, hopefully soon, vaccines. While the pandemic continues to wreak havoc, large corporations and small businesses are developing creative solutions to halt the spread of the virus.
Just as automakers famously shifted to make tanks and planes during World War II, today’s global giants — LVMH, Ford and GE to name a few — are retooling their production lines to help make everything from hand sanitizers to respirators. On the medical front, there are more than three dozen COVID-19 vaccines under development, a smart move considering that two out of every three vaccines for infectious diseases fail, according to a study by the Massachusetts Institute of Technology.
Forbes will continue to update this list of private companies and how they are stepping up to fight the COVID-19 pandemic:
Abbott Laboratories: Abbott Park, Illinois healthcare firm obtained emergency FDA authorization for its 5-minute coronavirus testing kit on March 27, with plans to start manufacturing 50,000 kits a day.
Alphabet: Through its healthcare arm Verily, Google’s parent company launched a website where users can find nearby testing sites in four California counties.
BioMérieux: French biotech company, founded by billionaire Alain Mérieux, received emergency FDA approval for its subsidiary’s new testing kit, which cuts testing times for the virus down to 45 minutes.
Cepheid: Sunnyvale, California molecular diagnostics company gained emergency FDA authorization for its new 45-minute COVID-19 testing kit.
Copan Diagnostics: Family-owned company located at the heart of Italy’s hard-hit Lombardy region makes diagnostic swabs for testing, airlifting 500,000 swabs to the U.S.
Mammoth Biosciences: South San Francisco-based biotech startup, founded by three 30 Under 30 alums, prototyped a rapid test by using the gene-editing tool Crispr to detect the disease.
Mesa Biotech: San Diego biotech business obtained FDA approval for its new 30-minute testing kit for COVID-19.
Puritan Medical Products: Maine-based diagnostic maker, one of the world’s largest makers of diagnostic swabs along with Italy’s Copan Diagnostics, is reportedly increasing production to make one million COVID-19 testing swabs a week.
AbbVie: North Chicago-based, publicly traded pharma firm is collaborating with authorities in the EU, the U.S. and China on experimental use of its HIV drug lopinavir/ritonavir to treat COVID-19.
AIM Immunotech: Florida-based pharmaceutical company announced on March 9 it would begin experimental testing of its chronic fatigue syndrome drug rintatolimod as a treatment for COVID-19 in Japan, at the National Institute of Infectious Diseases and the University of Tokyo.
Algernon Pharmaceuticals: Vancouver-based pharmaceutical firm is requesting FDA approval to begin trials of its chronic cough medication ifenprodil as a treatment for COVID-19.
AlloVir: Houston-based cell and gene therapy company is collaborating with Baylor College of Medicine to discover and develop T-cell therapies to fight COVID-19.
Apeiron Biologics: Vienna-based biotech firm started small-scale trials of its immunotherapy treatment on COVID-19 in China in February.
Ascletis: Hangzhou, China pharmaceutical company announced results of clinical trials of its antiviral drug danoprevir on COVID-19 patients in China; the small-scale study found that “danoprevir combined with ritonavir is safe and well tolerated in all patients.”
Bioxytran: Boston-based biotech outfit is developing a viral inhibitor to treat COVID-19.
Celltrion: South Korean healthcare firm is developing an antiviral treatment for COVID-19 as well as rapid self-testing kits that would provide results within fifteen to twenty minutes.
Cocrystal Pharma: Bothell, Washington pharma outfit is developing antivirals to treat COVID-19 using patents it recently acquired from the Kansas State University Research Foundation.
CytoDyn: Vancouver, Washington biotech firm announced preliminary results from three days of testing its antiviral drug leronlimab on COVID-19 patients in New York; the company stated in a press release that “test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab.”
Eli Lilly: Indianapolis pharma company is partnering with Vancouver-based biotech outfit AbCellera to develop antibody-based treatments for COVID-19.
Emergent BioSolutions: Maryland drugmaker is developing treatments derived from the antibodies found in the blood of people who tested positive for the disease.
EUSA Pharma: British pharmaceutical firm initiated trials of its siltuximab antibody treatment on COVID-19 patients at the Papa Giovanni XXIII hospital in Bergamo, Italy; the company released initial data on April 1 showing that one third of patients “experienced clinical improvement with reduced need for oxygen support” and a further 43% “saw their disease stabilise.”
Fujifilm Toyama Chemical: Tokyo-based conglomerate’s flu drug favipiravir has shown promising results in early clinical trials on COVID-19 patients in China, and the company is investing $83 million in its biological manufacturing capabilities.
Gilead: The Californian biotech giant initiated clinical trials in March for its antiviral drug remdesivir on patients in the U.S.
Harbour BioMed: Cambridge, Massachusetts biomedical firm announced a collaboration with New York’s Mount Sinai Health System to develop new human antibodies to treat COVID-19.
I-Mab Biopharma: Shanghai-based biopharma outfit announced it would begin clinical trials of its TJM2 antibody treatment on COVID-19 patients in the United States, with plans to expand to other countries affected by the pandemic.
Innovation Pharmaceuticals: Wakefield, Massachusetts biopharma firm is researching the use of its drug brilacidin — part of a category of investigational new drugs called defensin mimetics, which could have antimicrobial effects — as both a treatment and a vaccine for COVID-19, in separate efforts with a “major U.S. university” and with the Department of Health and Human Services.
ISR Immune System Regulation: Swedish immunotherapy firm’s subsidiary, ISR HBV, is conducting toxicological studies to determine whether its Immunolid ISR50 treatment could be used against COVID-19.
Kamada: Israeli pharmaceutical company is working on an antibody-based treatment for COVID-19 using the blood plasma of patients who recovered from the disease.
Mateon Therapeutics: Californian biopharma firm is testing a number of antiviral drugs as potential treatments for COVID-19 and is preparing to submit an application to the FDA in order to begin clinical trials on patients.
Merck KGaA: Darmstadt, Germany-based pharma multinational donated a supply of its multiple sclerosis drug interferon beta-1a to the French National Institute of Health and Medical Research in Paris for clinical trials on COVID-19 patients. The company’s North American life sciences arm, MilliporeSigma, is supplying several vaccine efforts with reagents and other essential raw products for vaccine development.
Mesoblast: Australian medical firm is working with authorities in the U.S., Australia, China and Europe to evaluate the use of its remestemcel-L drug to treat COVID-19.
Mylan: Pennsylvania-based pharmaceutical firm restarted production of hydroxychloroquine, a drug used to fight lupus, malaria and arthritis, at its West Virginia factory; the drug is being tested as a treatment for COVID-19 in human trials in New York.
Pluristem Therapeutics: Haifa, Israel-based medical company is developing a cell-based therapy to treat COVID-19, announcing on March 30 it had dosed three Israeli patients under a compassionate use program, with plans to enroll more.
Regeneron Pharmaceuticals: Westchester, New York biotech outfit, run by billionaires Leonard Schleifer and George Yancopoulos, is conducting clinical trials of its rheumatoid arthritis drug sarilumab, developed with French firm Sanofi, on patients in New York.
Roivant Sciences: Swiss pharma company is working with U.S. authorities to begin trials of its antibody treatment, gimsilumab, on COVID-19 patients.
Takeda: Japanese medical firm is working on hyperimmune therapy using blood plasma from previously infected patients.
AJ Vaccines: Danish vaccine developer is working on a COVID-19 vaccine that could hit the market in 2021.
Altimmune: The company is developing a novel intranasal vaccine for the coronavirus, making it one of three firms based in Gaithersburg, Maryland — along with Emergent Biosolutions and Novavax — that’s working on treatments and vaccines for COVID-19.
Arcturus Therapeutics: San Diego-based vaccine maker is developing a COVID-19 vaccine with researchers at the Duke-National University of Singapore medical school in Singapore.
Biocad: Russian drug developer is researching a COVID-19 vaccine, with animal trials scheduled for late April.
BioNTech: German biotech firm backed by billionaire twins Thomas and Andreas Struengmann is working to develop a coronavirus vaccine in partnership with Pfizer and Fosun Pharma, chaired by billionaire Guo Guangchang.
CanSino Biologics: Tianjin, China-based pharma company is starting clinical trials for its COVID-19 vaccine, using the vaccine technology deployed to develop the Ebola vaccine.
Codagenix: Melville, New York biotech firm is teaming up with the Serum Institute of India to develop a live-attenuated COVID-19 vaccine, which uses a live but weakened form of the virus.
CureVac: German firm, funded by billionaire Dietmar Hopp and the Bill and Melinda Gates Foundation, received $87 million from the European Commission to scale up development of its coronavirus vaccine.
Dyadic: Jupiter, Florida company is collaborating with the Israel Institute for Biological Research on both treatment and a vaccine against COVID-19, using the firm’s gene expression platform.
Dynavax: Emeryville, California vaccine maker is working with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Queensland to develop a COVID-19 vaccine.
ExpreS2ion: Danish biotech company received a grant of nearly $1 million from the European Union to develop a vaccine for COVID-19.
GeoVax: Atlanta-based medical company is collaborating with Wuhan-based BioVax to jointly produce a COVID-19 vaccine.
GlaxoSmithKline: British pharma titan is partnering with CEPI and Chengdu, China-based Clover Pharmaceuticals to use its pandemic vaccine adjuvant platform — which boosts the immune response in patients receiving a shot — to speed up development of COVID-19 vaccines.
Greffex: Houston-based genetic engineering firm is preparing to begin animal trials for its COVID-19 vaccine.
Heat Biologics: North Carolina biopharma company is developing a COVID-19 vaccine with the University of Miami.
iBio: Newark, Delaware biotech upstart is collaborating with Beijing-based CC-Pharming on the rapid development of a COVID-19 vaccine.
Inovio: Plymouth Meeting, Pennsylvania biotech business received $11.9 million in funding from the Department of Defense to rapidly produce a DNA vaccine for COVID-19 with drugmaker Ology Bioservices.
Johnson & Johnson: The company’s pharma unit, Janssen, will start manufacturing its vaccine — developed with the Department of Health and Human Services — this month, with human trials set to begin by September and a public rollout hoped for early 2021. The company and the federal government are investing more than $1 billion in the vaccine effort.
Novavax: Maryland-based vaccine maker received $4 million in funding from CEPI to accelerate development of its vaccine candidates, with clinical trials expected in the late spring.
Sanofi: French medical firm is working with the federal government and Massachusetts-based Translate Bio to expedite its coronavirus vaccine, using technology previously used to develop one for SARS.
Sorrento Therapeutics: San Diego-based biotech firm is teaming up with Cambridge, MA gene therapy company SmartPharm Therapeutics to develop a gene-encoded COVID-19 vaccine; it’s also working with Chinese drugmaker Mabpharm on a fusion protein treatment for the disease.
Themis Bioscience: Austrian biotech firm is part of a group, with the Institut Pasteur and the University of Pittsburgh, which received $4.9 million in initial funding from CEPI to build a COVID-19 vaccine modeled on the vaccine for measles.
Tonix Pharmaceuticals: New York-based pharma outfit is researching a potential COVID-19 vaccine based on the virus that causes horsepox.
Vaxart: San Francisco vaccine manufacturer Vaxart is working with Emergent Biosolutions to develop and manufacture an oral vaccine that can be taken as a tablet.
Vaxil: Israeli biotech startup began preclinical trials for its COVID-19 vaccine candidate.
Zydus Cadila: Indian pharma company announced it would fast-track development of a COVID-19 vaccine in February.
Protective Equipment And Sanitizer:
Anheuser-Busch InBev: The world’s largest beer company is making more than one million bottles of hand sanitizer from surplus alcohol at its breweries around the world.
Bacardi: The Bermuda-based spirits giant converted production at nine production facilities in Mexico, France, England, Italy, Scotland, Puerto Rico and the continental U.S. to make hand sanitizer.
Bulgari: The Italian luxury jeweler is manufacturing hand sanitizer with its fragrances partner, ICR, with plans to make hundreds of thousands of bottles by May.
Calzedonia Group: Italian retail clothing group, owned by billionaire Sandro Veronesi, converted production at several plants in Italy and Croatia to manufacture masks and medical gowns, with initial production of 10,000 masks a day.
Cantabria Labs: Spanish health products and cosmetics firm converted production at one of its factories to make hand sanitizer.
Consomed: Tunisian mask and medical equipment maker put all of its workers, more than 70% of which are reportedly women, on quarantine inside the company’s Kairouan factory to maximize production of protective gear.
Decathlon: Sporting goods empire founded by French billionaire Michel Leclercq partnered with Isinnova, a small engineering and design firm based in Italy, to convert snorkeling masks into respirators.
Diageo: The maker of Johnnie Walker whisky and Smirnoff vodka donated two million liters of ethyl alcohol, a byproduct of the distillation process, to hand sanitizer manufacturers.
Fiat Chrysler Automobiles: The multinational automaker announced on March 23 it would begin installing capacity to produce masks, which will be initially distributed in the U.S., Canada and Mexico.
Fippi: Italian diapers producer worked with the Lombardy region and the Polytechnic University of Milan to convert its factory to make up to 900,000 masks a day, which will go to frontline health workers facing a devastating outbreak in the region.
González Byass: Spanish spirits maker made three of its facilities and distilleries available to public health authorities for the production of hand sanitizer.
GVS: Family-owned Italian company is hiring more workers to expand production of ventilator filters and biohazard antivirus masks, destined for hospitals in Italy, the U.S. and China.
IKEA: Swedish furniture retailer is reportedly working with suppliers to increase production of masks, hand sanitizers, visors and aprons; the company also opened a drive-through COVID-19 testing facility with the UK’s National Health Service at its store in the Wembley area of London.
Ineos: Billionaire James Ratcliffe’s chemical powerhouse Ineos is building a new hand sanitizer plant in the UK — which will be ready in just 10 days — to produce a million bottles a month, and plans to build another in Germany.
Massaflex: Italian mattress maker converted all production at its factory in Tuscany to make masks.
Medline: Northfield, Illinois family-owned manufacturer is ramping up production to supply medical masks, biohazard bags, surgical clothing and disinfectants to hospitals across the United States.
Menarini: Pharma firm, owned by Italian billionaire Massimiliana Landini Aleotti and her three children, converted a production line at its Florence factory to make disinfectant gel that will be distributed free of charge to Italy’s civil protection agency.
Miroglio Group: Italian fashion group converted production at its factories in the northwestern Italian region of Piedmont to make up to 100,000 masks a day.
Pernod Ricard: French spirit maker’s U.S. branch is producing hand sanitizer at four distilleries in Arkansas, Kentucky, Texas and West Virginia.
Prada: On March 23, the luxury fashion empire — led by billionaire couple Miuccia Prada and Patrizio Bertelli — announced it would convert production at its factory in Perugia to make 80,000 medical overalls and 110,000 masks for healthcare workers in the Tuscany region.
Top Glove: Malaysian medical glove maker, one of the world’s largest, is ramping up production and has donated more than 5 million gloves to authorities in China and Malaysia.
Ventilators And Beds:
BAE Systems: British aerospace company is part of the Ventilator Challenge UK Consortium.
Bloom Energy: San Jose, California-based fuel cell maker is refurbishing unused and out-of-warranty ventilators in a partnership with Philadelphia-based appliance distributor Almo Corporation, which will then ship them to state agencies and hospitals across the U.S.
BreathDirect: Long Beach-based startup was recently established by Darren Saravis, CEO of medical device firm Nectar, to quickly produce 3,500 ventilators a week by May at $10,000 each.
Ford: Auto giant is working with 3M and GE’s healthcare unit to make ventilators, respirators and face shields at its manufacturing sites; Ford and GE Healthcare announced on March 30 that the companies would produce 50,000 ventilators by July 8 with plans to increase production to 30,000 a month.
General Motors: The auto titan announced on March 27 it would start building ventilators at its Kokomo, IN plant in a partnership with medical device maker Ventec Life Systems, as well as producing masks at a factory in Michigan. Hours later, President Donald Trump invoked the Defense Production Act to compel GM to “accept, perform and prioritize federal contracts for ventilators.”
GKN Aerospace: British aerospace firm is a member of the Ventilator Challenge UK Consortium.
Inspiration Healthcare: British medical devices maker is part of the Ventilator Challenge UK Consortium.
Mahindra Group: Mumbai-based conglomerate, owned by billionaire Anand Mahindra and his family, announced it would begin producing ventilators at plants in India, reportedly pricing them at less than $100 each.
Malvestio: Italian maker of ICU and hospital beds is ramping up production by 30-40% to meet a surge in demand for its beds from hospitals in Italy.
Meggitt: British aerospace and defense components maker is a member of the Ventilator Challenge UK Consortium.
Penlon: Oxford-based medical device maker is part of the Ventilator Challenge UK Consortium.
Philips: The Dutch multinational is doubling production of pulmonary ventilators, with plans to quadruple it by the third quarter of 2020.
Rolls-Royce: The luxury carmaker is a member of the Ventilator Challenge UK Consortium.
SIARE Engineering: Italy’s largest ventilator producer enlisted the help of Italian army technicians and employees from Fiat Chrysler and Ferrari to ramp up production.
Smiths Group: British engineering firm is part of the Ventilator Challenge UK Consortium.
Thales Group: French aerospace multinational is a member of the Ventilator Challenge UK Consortium.
Ultra Electronics: British defense systems provider is part of the Ventilator Challenge UK Consortium.
Supporting Healthcare Workers And First Responders:
Airbnb: The peer-to-peer home rental company, cofounded by billionaires Brian Chesky, Nathan Blecharczyk and Joe Gebbia, is providing housing for 100,000 COVID-19 responders in homes volunteered by Airbnb hosts around the world.
GlobeKeeper: Tel Aviv-based security app developer worked with Israel’s Health Ministry to launch a voluntary tracking app which allows users to report their exposure to COVID-19; the company is reportedly rolling out its own coronavirus-tracking app, named SAFE, in India next week with plans to expand to other countries.
GoPuff: Late-night delivery app popular with college students is pivoting to deliver essential supplies to healthcare workers at hospitals in Chicago, Philadelphia and Washington D.C.
Inditex: The Spanish fast fashion giant behind Zara and other brands, majority-owned by billionaire Amancio Ortega, is making its logistics and procurement network available to the Spanish government to coordinate supply of materials needed to make masks, gloves, face shields and other protective equipment.
Palantir: Big data firm, cofounded and chaired by billionaire Peter Thiel, is working with the U.S. Centers for Disease Control and the UK’s National Health Service on coronavirus-tracking software based on its data gathering and analysis technology platform, Palantir Foundry.
Originally posted @ Forbes